LONDON, UK – July 08, 2013 – BCSI, a leading medical device provider and tech²ART, specialists in Assisted Reproduction Technology (ART), announced a partnership today during the annual meeting of European Society of Human Reproduction and Embryology (ESHRE). The two companies will collaborate on bringing new technologies to market to address current issues in pH monitoring for Invitro Fertilizaton (IVF) and other uses.
“Bringing together global experts in ART is an important part of the effort to improve outcomes for clinics and families,” said Russ Aldrich, CEO, BCSI. “The tech²ART team is energetic and focused and we look forward to a successful partnership.”
“BCSI and the SAFE Sens technology they’ve created have an opportunity to make a real impact,” said Michael Similie, General Manager, tech²ART. “Our companies respective strengths are very synergistic and should bring better outcomes faster as we work together to get the technology into clinics.”
About tech²ART
tech²ART Inc. www.tech2art.com is a privately held company that designs, manufactures and markets laboratory equipment primary to the Assisted Reproductive Technology (ART), Embryonic Stem Cell (ESC) and Life Science segment. The rationale for tech²ART is a desire and an ambition to create a strong alternative to current technologies based on a ‘Best in Class’ business model and a customized technology to cover the market needs.
###
tech²ART, and the tech²ART logo are trademarks of tech²ART. BCSI, SAFE Sens and the BCSI logo are trademarks of BCSI. All other names or product names mentioned in this release are trademarks or registered trademarks of their respective companies.